Trends in Invasive Cutaneous Melanoma in Saskatchewan 1970-1999

Journal of Cutaneous Medicine and Surgery

Volumn 7, Issue 6, 2003, Pages 433-442

  Ulmer, Marcie J ^a,d   Tonita, Jon M ^b   Hull, Peter R ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b SASKATCHEWAN CANCER AGENCY   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CANADA; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CANCER SURVIVAL; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW; SKIN CANCER; STATISTICAL MODEL;

CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; INCIDENCE; MALE; MELANOMA; NEOPLASM INVASIVENESS; POPULATION SURVEILLANCE; PROGNOSIS; REGISTRIES; REGRESSION ANALYSIS; RISK FACTORS; SASKATCHEWAN; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 1242352547     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-003-0159-0     Document Type: Review

References (83)

1. Wingo P, Ries L, Giovino G, et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999; 91:675-690.
2. Armstrong B, English D. Cutaneous malignant melanoma. In: Schottenfeld D, Fraumeni J, Eds. Cancer epidemiology, and prevention New York: Oxford University Press, 1996, pp 1282-1312.
3. Armstrong B, Kricker A. Cutaneous melanoma. In: Doll R, Fraumeni J, Muir C, Eds. Cancer surveys: Trends in cancer incidence and mortality Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1994, pp 219-240.
4. Parkin D, Whelan S, Ferlay J. Cancer incidence in five continents VII. IARC Sci. Publ. No. 143.International Agency for Research on Cancer, Lyon 1997.
5. Gaudette L, Gao R-N, et al. Changing trends in melanoma incidence and mortality. Health Rep 1998; Autumn 10(2):29-41.
6. Venzon D, Moolgavkar S. Cohort analysis of malignant melanoma in five countries. Am J Epidemiol 1984; 119(1):62-70.
7. Kricker A, Armstrong B, Jones M. Health, solar UV radiation and environmental change. IARC Tech. Rep. No. 13.International Agency for Research on Cancer, Lyon 1993.
8. Berwick M, et al. Why are people still dying from melanoma?. Arch Dermatol 1999; 135:1534-1536.
9. MacNeill I, Elwood J, Miller D, et al. Trends in mortality from melanoma in Canada and prediction of future rates. Stat Med 1995; 14:821-839.
10. Chen V, Wu X. Cancerin North America, 1990-94.North American Association of Central Cancer Registries, Sacramento, CA 1998.
11. Percy C, Van Holten V, Muir C. International classification of diseases for oncology, 2nd ed.World Health Organization, Geneva 1990.
12. Hennekens C, Buring J. Measures of disease frequency and association. In: Mayrent S, Eds. Epidemiology in Medicine. Boston: Little, Brown, 1987, pp 54-101.
13. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 1982; 38:933-942.
14. Brown C. The statistical comparison of relative survival rates. Biometrics 1983; 39:941-948.
15. Voutilainen E, Dickman P, Hakulinen T. Surv 2: Relative survival analysis program. Finnish Cancer Registry and Cancer Epidemiology Unit, Helsinki, Finland, and Stockholm, Sweden 1998.
16. Francis B, Green M, Payne C. GLIM 4: The statistical system for generalized linear interactive modelling. Oxford University Press, Oxford 1994.
17. Dean A, Dean J, Coulombier D. Epi Info: A word-processing, database, and statistics program for public health on IBM-compatible microcomputers. Centers for Disease Control and Prevention, Atlanta, GA 1994.
18. Bulliard J, Cox B, Semenciw R, et al. Trends by anatomic site in the incidence of cutaneous malignant melanoma in Canada, 1969-93. Cancer Causes Control 1999; 10:407-416.
19. Cavalieri R, Macchini V, Mostaccioli S, et al. Time trends in features of cutaneous melanoma at diagnosis: Central-South Italy, 1962-1991. Ann Ist Super Sanita 1993; 29:469-472.
20. MacKie R, Hunter J, Aitchison T. Cutaneous malignant melanoma, Scotland, 1979-89. Lancet 1992; 339:971-975.
21. Brown L, Palmer P. Melanoma incidence in Tauranga 1980-9. N Z Med J 1991; 104(908):109-111.
22. MacLennan R, Green A, McLeod G, et al. Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst 1992; 84(18):1427-1432.
23. Dennis L. Analysis of the melanoma epidemic, both apparent and real. Arch Dermatol 1999; 135:275-280.
24. Burton R, Coates M, Hersey P, et al. An analysis of a melanoma epidemic. Int J Cancer 1993; 55:765-770.
25. Swerlick R, Chen S. The melanoma epidemic: More apparent than real?. Mayo Clin Proc 1997; 72:559-564.
26. Burton R. Analysis of public education and the implications with regard to nonprogressive thin melanomas. Curr Opin Oncol 1995; 7:170-174.
27. Burton R, Armstrong B. Current melanoma epidemic: A nonmetastasizing form of melanoma. World J Surg 1995; 19:330-333.
28. Burton R, Armstrong B. Recent incidence trends imply a nonmetastasizing form of invasive melanoma. Melanoma Res 1994; 4:107-113.
29. Burton R, Armstrong B. Non-metastasizing melanoma?. J Surg Oncol 1998; 67:73-76.
30. Holman C, Mulroney C, Armstrong B. Epidemiology of pre-invasive and invasive malignant melanoma in western Australia. Int J Cancer 1980; 25:317-323.
31. Magnus K. Habits of sun exposure and risk of malignant melanoma: An analysis of incidence rates in Norway: 1955-1977 by cohort, sex, age, and primary tumor site. Cancer 1981; 48:2329-2335.
32. Newell G, Sider J, Bergfelt L, et al. Incidence of cutaneous melanoma in the United States by histology with special reference to the face. Cancer Res 1988; 48(17):5036-5041.
33. Cohen H, Cox E, Manton K, et al. Malignant melanoma in the elderly. J Clin Oncol 1987; 5(1):100-106.
34. Fisher S. Cutaneous malignant melanoma of the head and neck. Laryngoscope 1989; 99:822-836.
35. Gillgren P, Mansson-Brahme E, Frisell J, et al. Epidemiological characteristics of cutaneous malignant melanoma of the head and neck: A population-based study. Acta Oncol 1999; 38(8):1069-1074.
36. Elwood J, Gallagher R. Body site distribution of cutaneous malignant melanoma in relationship to patterns of sun exposure. Int J Cancer 1998; 78:276-280.
37. Muir C, Waterhouse J, Mack T. Cancer incidence in five continents V. IARC Sci. Publ. No. 88.International Agency for Research on Cancer, Lyon 1987.
38. Hersey P, Sillar R, Howe C, et al. Factors related to the presentation of patients with thick primary melanomas. Med J Aust 1991; 154:583-587.
39. Jelfs P, Giles G, Shugg D, et al. Cutaneous malignant melanoma in Australia, 1989. Med J Aust 1994; 161:182-187.
40. Chen Y-T, Dubrow R, Holford T, et al. Malignant melanoma risk factors by anatomic site: A case-control study and polychotomous logistic regression analysis. Int J Cancer 1996; 67:636-643.
41. Cress R, Holly E, Ahn D, et al. Cutaneous melanoma in women: anatomic distribution in relation to sun exposure and phenotype. Cancer Epidemiol Biomarkers Prev 1995; 4:831-836.
42. Crombie I. Distribution of malignant melanoma on the body surface. Br J Cancer 1981; 43:842-849.
43. Dennis L, White E, Lee J. Recent cohort trends in malignant melanoma by anatomic site in the United States. Cancer Causes Control 1993; 4:93-100.
44. Gallagher R, Ma B, McLean D. Trends in basal cell carcinoma, squamous cell carcinoma, and melanoma of the skin from 1973 through 1987. J Am Acad Dermatol 1990; 23:413-421.
45. Masback A, Westerdahl J, Ingvar C, et al. Cutaneous malignant melanoma in South Sweden 1965, 1975, and 1985. Cancer 1994; 73(6):1625-1630.
46. Hall H, Miller D, Rogers J, et al. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 1999; 40(1):35-42.
47. Brady M, Oliveria S, Christos P, et al. Patterns of detection in patients with cutaneous melanoma: Implications for secondary prevention. Cancer 2000; 89:342-347.
48. Koh H, Miller D, Geller A, et al. Who discovers melanoma?. J Am Acad Dermatol 1992; 26(6):914-919.
49. Epstein D, Lange J, Gruber S, et al. Is physician detection associated with thinner melanomas?. JAMA 1999; 281(7):640-643.
50. Girgis A, Campbell E, Redman S, et al. Screening for melanoma: A community survey of prevalence and predictors. Med J Aust 1991; 154:338-343.
51. Miller D, Geller A, Wyatt S, et al. Melanoma awareness and self-examination practices: Results of a United States survey. J Am Acad Dermatol 1996; 34(6):962-970.
52. Douglass H, McGee R, Williams S. Are young adults checking their skin for melanoma?. Aust N Z J Public Health 1998; 22:562-567.
53. MacKie R, Hole D. Audit of public education campaign to encourage earlier detection of malignant melanoma. BMJ 1992; 304:1012-1015.
54. Coleman M, Esteve J, Damiecki P. Trends in cancer incidence and mortality. IARC Tech. Rep. No. 121.International Agency for Research on Cancer Scientific Publications, Lyon 1993.
55. MacKie R, Hole D, Hunter J, et al. Cutaneous malignant melanoma in Scotland: Incidence, survival, and mortality, 1979-94. BMJ 1997; 315:1117-1121.
56. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist L, et al. Trends in mortality from malignant melanoma in Sweden, 1970-1996. Cancer 2000; 89(2):348-355.
57. La Vecchia C, Lucchini F, Negri E, et al. Recent declines in worldwide mortality from cutaneous melanoma in youth and middle age. Int J Cancer 1999; 81:62-66.
58. Percy C, Stanek E, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health 1981; 71(3):242-250.
59. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172(5):902-908.
60. Sahin S, Rao B, Kopf A, et al. Predicting ten-year survival of patients with primary cutaneous melanoma: Corroboration of a prognostic model. Cancer 1997; 80(8):1426-1431.
61. Balch C, Soong S-J, Murad T, et al. A multifactorial analysis of melanoma II. Prognostic factors in patients with stage I (localized) melanoma. Surgery 1979; 86(2):343-351.
62. Shaw H, Balch C, Soong S-J, et al. Prognostic histopathological factors in malignant melanoma. Pathology 1985; 17:271-274.
63. Soong S-J, Shaw H, Balch C, et al. Predicting survival and recurrence in localized melanoma: A multivariate approach. World J Surg 1992; 16:191-195.
64. Worth A, Gallagher R, Elwood J, et al. Pathologic prognostic factors for cutaneous malignant melanoma: The Western Canada melanoma study. Int J Cancer 1989; 43:370-375.
65. Thorn M, Adami H-O, Ringborg U, et al. Long-tenn survival in malignant melanoma with special reference to age and sex as prognostic factors. J Natl Cancer Inst 1987; 79(5):969-974.
66. Karjalainen S, Hakulinen T. Survival and prognostic factors of patients with skin melanoma: A regression-model analysis based on nationwide cancer registry data. Cancer 1988; 62:2274-2280.
67. Austin P, Cruse C, Lyman G, et al. Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol 1994; 1(6):487-494.
68. Schuchter L, Schultz D, Synnestvedt M, et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. Ann Intern Med 1996; 125(5):369-375.
69. Cascinelli N, Morabito A, Bufalino R, et al. Prognosis of stage I melanoma of the skin. Int J Cancer 1980; 26:733-739.
70. Rivers J, Kelly M, Kopf A, et al. Age and malignant melanoma: Comparison of variables in different age-groups. J Am Acad Dermatol 1989; 21(4):717-722.
71. Rogers G, Kopf A, Rigel D, et al. Effect of anatomical location on prognosis in patients with clinical stage I melanoma. Arch Dermatol 1983; 119:644-649.
72. Crowley N, Seigler H. Late recurrence of malignant melanoma: Analysis of 168 patients. Ann Surg 1990; 212(2):173-177.
73. Drzewiecki K, Frydman H, Anderson K, et al. Malignant melanoma: Changing trends in factors influencing metastasis-free survival from 1964-1982. Cancer 1990; 65:362-366.
74. Day C, Sober A, Kopf A, et al. A prognostic model for clinical stage I melanoma of the upper extremity: The importance of anatomical subsites in predicting recurrent disease. Ann Surg 1981; 193(4):436-440.
75. Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma: Prognostic classificafion of anatomic location. Cancer 1995; 75(10):2492-2498.
76. Thorn M, Ponten F, Bergstrom R, et al. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst 1994; 86(10):761-769.
77. Berwick M, Dubin N, Luo S-T, et al. No improvement in survival from melanoma diagnosed from 1973 to 1984. Int J Epidemiol 1994; 23(4):673-681.
78. Clark W, Elder D, Guerry D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81(24):1893-1904.
79. Smith J, Whatley P, Redburn J. Improving survival of melanoma patients in Europe since 1978. Eur J Cancer 1998; 34(14):2197-2203.
80. Stadelmann W, Rapaport D, Soong S-J. Prognostic clinical and pathological features. In: Balch C, Houghton A, Sober A, Eds. Cutaneous melanoma, 3rd ed St. Louis: Quality Medical Publishing Inc., 1998, pp 11-35.
81. Ellison L, Gibbons L, et al. Five-year relative survival from prostate, breast, colorectal and lung cancer. Health Rep 2001; 13(1):23-24 the Canadian Cancer Survival Analysis Group.
82. Tan L, Robson D. Trends in cancer survival in Saskatchewan 1967 to 1986. Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, June 1991.
83. Balch C, Soong S-J, Gershenwald J, et al. Prognostic factors analysis in 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001; 19(16):3622-3634.